ADOPT data not major setback for Eliquis from BMS/Pfizer
14 November 2011
Eleanor Malone
Please Login to read the full article.
14 November 2011
Eleanor Malone
eleanor.malone@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- BMS/Pfizer's Eliquis better than Lovenox, but comparison with Pradaxa and Xarelto not clear, says NICE
- ARISTOTLE: changing thinking about BMS/Pfizer's Eliquis in anticoagulation?
- BMS/Pfizer's Eliquis better than Sanofi's Lovenox for hip but not knee, IQWiG says
- Astellas' darexaban in ACS – value far above RUBY-1?
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
